JP2024517879A - 放射性金属用キレート剤ならびにその製造方法および使用方法 - Google Patents

放射性金属用キレート剤ならびにその製造方法および使用方法 Download PDF

Info

Publication number
JP2024517879A
JP2024517879A JP2023568386A JP2023568386A JP2024517879A JP 2024517879 A JP2024517879 A JP 2024517879A JP 2023568386 A JP2023568386 A JP 2023568386A JP 2023568386 A JP2023568386 A JP 2023568386A JP 2024517879 A JP2024517879 A JP 2024517879A
Authority
JP
Japan
Prior art keywords
vivo
radioisotope
noneunpax
peptide
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517879A5 (enExample
Inventor
ウォートン、ルーク
オーヴィグ、クリス
Original Assignee
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア filed Critical ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア
Publication of JP2024517879A publication Critical patent/JP2024517879A/ja
Publication of JP2024517879A5 publication Critical patent/JP2024517879A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023568386A 2021-05-07 2022-05-06 放射性金属用キレート剤ならびにその製造方法および使用方法 Pending JP2024517879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185951P 2021-05-07 2021-05-07
US63/185,951 2021-05-07
PCT/CA2022/050712 WO2022232943A1 (en) 2021-05-07 2022-05-06 Chelators for radiometals and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2024517879A true JP2024517879A (ja) 2024-04-23
JP2024517879A5 JP2024517879A5 (enExample) 2025-05-09

Family

ID=83931919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568386A Pending JP2024517879A (ja) 2021-05-07 2022-05-06 放射性金属用キレート剤ならびにその製造方法および使用方法

Country Status (7)

Country Link
US (1) US20240254085A1 (enExample)
EP (1) EP4334290A4 (enExample)
JP (1) JP2024517879A (enExample)
AU (1) AU2022271362A1 (enExample)
CA (1) CA3217801A1 (enExample)
WO (1) WO2022232943A1 (enExample)
ZA (1) ZA202310013B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186328A1 (en) * 2019-03-20 2020-09-24 The University Of British Columbia Chelators and methods of making and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186328A1 (en) * 2019-03-20 2020-09-24 The University Of British Columbia Chelators and methods of making and using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEMISTRY, vol. Vol. 33, Issue 7, JPN6026021648, 2022, pages 1422 - 1436, ISSN: 0005875071 *
BIOCONJUGATE CHEMISTRY, vol. Vol. 36, Issue 6, JPN6026021650, 2025, pages 1273 - 1287, ISSN: 0005875069 *
INORGANIC CHEMISTRY, vol. Vol. 60, Issue 6, JPN6026021652, 2021, pages 4076 - 4092, ISSN: 0005875067 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. Vol. 66, Issue 19, JPN6026021649, 2023, pages 13705 - 13730, ISSN: 0005875070 *
RSC ADVANCES, vol. Vol. 5, Issue 43, JPN6026021651, 2015, pages 33963 - 33973, ISSN: 0005875068 *

Also Published As

Publication number Publication date
US20240254085A1 (en) 2024-08-01
WO2022232943A1 (en) 2022-11-10
CA3217801A1 (en) 2022-11-10
EP4334290A4 (en) 2026-01-28
EP4334290A1 (en) 2024-03-13
AU2022271362A1 (en) 2023-11-16
ZA202310013B (en) 2024-05-30

Similar Documents

Publication Publication Date Title
JP2022513256A (ja) デュアルモード１８ｆ標識セラノスティック化合物及びその使用
EP3689892B1 (en) Radioactive drug
EP4537851A1 (en) Trifunctional compound and use thereof
EP2654803B1 (en) Radiolabeled her2-binding peptide conjugates
CA3172811A1 (en) Chelator compositions for radiometals and methods of using same
JP7646637B2 (ja) 画像化及び治療用組成物
CA3175154A1 (en) Chelators and methods of making and using same
Wharton et al. Rearmed bifunctional chelating ligand for 225Ac/155Tb precision-guided theranostic radiopharmaceuticals─ H4noneunpaX
EP2661284A1 (en) Her2 binding peptides labelled with a 18f - containing organosilicon compound
Wharton et al. H4picoopa─ Robust chelate for 225Ac/111In theranostics
CN117042812A (zh) 用于诊断和治疗用途的cxcr4-配体及其前体
Radford et al. Synthesis and evaluation of Re/99mTc (I) complexes bearing a somatostatin receptor-targeting antagonist and labeled via a novel [N, S, O] clickable bifunctional chelating agent
Läppchen et al. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
Southcott et al. Trastuzumab-conjugated oxine-based ligand for [89Zr] Zr4+ immunoPET
US20240254085A1 (en) Chelators for radiometals and methods of making and using same
EP4291251B1 (en) Her2-binding polypeptide
JP2025540658A (ja) 神経ペプチドｙ１受容体（ｎｐｙ１ｒ）を標的とした治療薬およびその使用
Russelli Development of innovative chelators for the synthesis of 89Zr and [18F] AlF protein-based PET tracers
EP4230637A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
Verhoeven et al. A Peptide-based Pretargeting Approach with TCO-functionalized NeoB Conjugates for Theranostics of GRPR-positive Cancers
EA051630B1 (ru) Радиоактивные комплексы анти-her2 антитела и радиофармацевтическое средство
WO2025156030A1 (en) 1,7,13-trioxa-4,10,16-triazacyclooctadecane chelator compositions for radiometals and methods of using same
HK40029075A (en) Radioactive drug
KR20230163487A (ko) 항egfr 항체의 방사성 복합체 및 방사성 의약
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602